250 000名联合王国国民保健制度的病人获得除糖尿病治疗之外的减重药物Mounjaro。 250,000 UK NHS patients gain access to weight loss drug Mounjaro beyond diabetes treatment.

Mounjaro(tirzepatide)是一种减重药物,不久将向联合王国近250 000名国民保健制度的病人提供,扩大治疗范围,超越糖尿病治疗。 Mounjaro (tirzepatide), a weight loss drug, will soon be available to nearly 250,000 NHS patients in the UK, expanding access beyond diabetes treatment. 它模仿发出饱腹感信号的激素，证明比 semaglutide 更有效地减轻体重。 It mimics hormones that signal fullness, proving more effective than semaglutide for weight loss. 但是,在提供专家减重服务的同时,还要提供这种服务,人们担心潜在的供应问题和需求增加会影响糖尿病患者的获得。 However, it will be prescribed alongside specialist weight loss services, and there are concerns about potential supply issues and increased demand affecting access for diabetes patients.